Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, announced on Monday its financial results for the fiscal year ended 31 March 2025.
Revenue totalled USD119.97m, down from USD123.99m in the same period of last year.
Gross profit was USD3.84m, compared to USD4.88m a year earlier, while gross margin was 3.2% compared to 3.9% in the year to 31 March 2024.
Ridgetech reported net income of USD10.20m, or USD1.84 per basic and diluted earnings per share, compared to a net loss of USD4.23m, or USD2.93 per basic and diluted loss per share, for the same period a year ago.
As of 31 March 2025 the company had cash and cash equivalents of USD12.78m, an increase from USD2.30m as of 31 March 2024.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025